Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4WF8

Crystal structure of NS3/4A protease in complex with Asunaprevir

4WF8 の概要
エントリーDOI10.2210/pdb4wf8/pdb
分子名称NS3 protein, ZINC ION, CHLORIDE ION, ... (5 entities in total)
機能のキーワードhcv protease inhibitor complex, resistance, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
由来する生物種Hepatitis C virus
タンパク質・核酸の鎖数1
化学式量合計21105.05
構造登録者
Schiffer, C.A.,Soumana, D.I.,Ali, A. (登録日: 2014-09-13, 公開日: 2014-10-08, 最終更新日: 2023-12-27)
主引用文献Soumana, D.I.,Ali, A.,Schiffer, C.A.
Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease.
Acs Chem.Biol., 9:2485-2490, 2014
Cited by
PubMed Abstract: Asunaprevir (ASV), an isoquinoline-based competitive inhibitor targeting the hepatitis C virus (HCV) NS3/4A protease, is very potent in vivo. However, the potency is significantly compromised by the drug resistance mutations R155K and D168A. In this study three crystal structures of ASV and an analogue were determined to analyze the structural basis of drug resistance susceptibility. These structures revealed that ASV makes extensive contacts with Arg155 outside the substrate envelope. Arg155 in turn is stabilized by Asp168, and thus when either residue is mutated, the enzyme's interaction with ASV's P2* isoquinoline is disrupted. Adding a P1-P3 macrocycle to ASV enhances the inhibitor's resistance barrier, likely due to poising the inhibitor to its bound conformation. Macrocyclic inhibitors with P2* extension moieties avoiding interaction with the protease S2 residues including Arg155 must be chosen for future design of more robust protease inhibitors.
PubMed: 25243902
DOI: 10.1021/cb5006118
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.7 Å)
構造検証レポート
Validation report summary of 4wf8
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon